Sanofi (SNY) Debt Ratio (2009 - 2026)

Sanofi (SNY) posted Debt Ratio of 0.17 for Q2 2026, up 14.54% sequentially from 0.15 in Q4 2025, and up 2.31% YoY from 0.16 in Q2 2025.

Sanofi (SNY) Debt Ratio (2009 - 2026) Analysis & Trends

Sanofi has reported Debt Ratio for 18 years, with the latest figure at 0.17 in Q2 2026.

Quarterly Debt Ratio rose 2.31% year-over-year to 0.17 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.17 (up 2.31% YoY) and the FY2025 annual result came in at 0.15, up 21.68% from the prior year.
Debt Ratio grew to 0.17 in Q2 2026 per SNY's latest filing, from 0.15 in the prior quarter.
Over five years, Debt Ratio peaked at 0.17 in Q2 2026 and troughed at 0.12 in Q4 2024.
A 5-year average of 0.15 and a median of 0.15 in 2023 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2023 and 2025: Debt Ratio declined 13.69% in 2023, then increased 21.68% in 2025.
Over 5 years, Debt Ratio stood at 0.15 in 2022, then slipped by 13.69% to 0.13 in 2023, then retreated by 7.05% to 0.12 in 2024, then increased by 21.68% to 0.15 in 2025, then gained by 14.54% to 0.17 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.17, 0.15, and 0.16 for Q2 2026, Q4 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Johnson & Johnson	654.04 Bn	633.28 Bn	17.26 Bn	0.24
2	AbbVie	470.61 Bn	464.04 Bn	12.70 Bn	0.52
3	Merck	379.00 Bn	371.86 Bn	12.21 Bn	0.42
4	Novartis Ag	303.30 Bn	295.61 Bn	11.24 Bn	0.08
5	Astrazeneca	258.47 Bn	253.57 Bn	12.86 Bn	0.25
6	Amgen	237.78 Bn	223.79 Bn	7.24 Bn	0.66
7	Gilead Sciences	183.75 Bn	180.57 Bn	6.22 Bn	0.58
8	Pfizer	160.91 Bn	149.21 Bn	10.94 Bn	0.31
9	Gsk	106.07 Bn	101.90 Bn	8.24 Bn	-0.31
10	Sanofi	55.31 Bn	47.93 Bn	10.79 Bn	0.17

Download Data